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Severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2)
infection is the gravest current challenge worldwide, with
approximately 5 million infected patients, more than 300,000
deaths, and an overallmortality rate of approximately 7% at the
time of writing.1 Although the underlying disease, coronavirus
disease 2019 (COVID-19), is themajormedical challenge for the
general population, it is more threatening for patients with
underlying risk factors such as diabetes, cardiovascular disor-
ders, hypertension, obesity, cancer, and chronic renal and
hepatic failures.2 Coagulopathy is a major pathophysiological
characteristic of COVID-19, and the virus can affect all patients
including those with congenital bleeding disorders (CBDs).
However, due to a paucity of data, it is not clear whether these
patients aremoreor lessprone to thesevere formof thedisease.
In thiscontext,wereportourobservationsofCOVID-19patients
withCBDs. For thispurpose,wecollected laboratoryandclinical
data of patients with identified CBDs receiving a diagnosis of
COVID-19 with reverse transcriptase–polymerase chain reac-
tion (RT-PCR) and/or a computed tomography (CT) scan. The
latter is now an accepted surrogate marker of COVID-19, in
particular ground-glass opacities,whenaligned toother clinical
features of COVID-19,3,4 considering also thepotential for false-
negative RT-PCR. Clinical presentations and laboratory pheno-
types for our patient cohort were collected through patient
interviews andmedical files. Nine patients could be identified,
whowere noted to be suffering from hemophilia A (HA) (n¼ 5
[55.5%]), von Willebrand disease (VWD) (n¼ 2 [22.2%]), he-
mophiliaB (HB) (n¼ 1 [11.1%]), and factor XIII (FXIII) deficiency
(n¼ 1 [11.1%]). All butoneof thesepatients (n¼ 8 [89%])were
male, with a mean age of 48.2 years (range: 26–59 years), and
most were symptomatic with COVID-19 at the time of SARS-
CoV-2 infection (n¼ 7 [78%]). Of interest, two were asymp-
tomatic for COVID-19: one was a hospital employee identified
to have SARS-CoV-2 following routine employee screening and
another was randomly referred to undergo testing. Among the
nine patients, two (22%) experienced bleeding and one
(11%) experienced thrombosis. Both patients with bleeding
events had contributing risk factors: one with lymphoma and
anotherwith factorVIII inhibitor. Thrombosiswasobserved ina
young patient with type 1 VWD, the only hospitalized patient,
whowas treated in the intensive care unit for 2 days. It isworth
noting that this was the patient who was RT-PCR-negative for
SARS-CoV-2 and was hence hospitalized based on CT findings
and clinical presentation. Although molecular studies failed to
confirm an active infection by SARS-CoV-2 at admission, we
believe thismay have been a false-negativefinding, and further
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repeat testing was not performed. D-dimer was only available
for two patients, with these yielding normal results, and
prothrombin time (PT) also was normal in all cases with
available data (n¼ 4). Platelet count was also available in four
cases; only one of these experienced mild thrombocytopenia
(►Table 1).
COVID-19 is a relatively severe infectious disease, with a
cumulativemortality rate of approximately 7%,1 but we did not
haveanymortality inourcohort.Thedisease ismoresevereand
profound in patients with underlying risk factors, whereas the
effect of the disease on patients with CBDs is currently largely
unknown. Only one case with severe HA and mild COVID-19-
related symptoms has been reported up to now.5 Since hyper-
coagulability is a common feature of COVID-19, the effect of a
disorder with such a feature on patients with congenital
hypocoagulability is illuminating. In this study, we tried to
collect data for all SARS-CoV-2 infected patientswithCBDs, but
we are certain that some infected patients with CBD, even
symptomaticones,weremissed inour search.Duringourstudy,
no death was observed among patients with CBDs and COVID-
19 despite a mean age of approximately 50 years. Only one
patient needing hospitalization experienced a thrombotic
event; thiswasacaseofmild type1VWD.Although thrombosis
is a (rare) presentation in VWD, it is a multifactorial phenome-
non, with the majority of affected individuals being type 1
VWD.6 Apart from this one patient, no other thrombotic event
and no hospitalization were observed in our patient cohort.
Two patients with further risk factors experienced bleeding,
with one patient’s bleeding similar to his usual pattern. Gas-
trointestinal bleeding, the most common hemorrhagic mani-
festation in COVID-19, has been reportedwith a frequency of 4
to13.7%,mostly inseverelyaffectedpatients.7 In thisstudy,only
two patients with contributing risk factors experienced bleed-
ing during COVID-19 infection, even including those with
severefactordeficiencies.An interestingevidencethatemerged
from this study is the absence of thrombotic events in seven
patientswithmoderate-to-severe factor deficiencies. This is an
important finding, which might result in lower overall rates of
morbidity and mortality among patients with CBDs. It should
be noted that none of the patients in our cohort were receiving
regular prophylaxis prior to the pandemic, except the severely
affected HB and FXIII deficient patients. Patient with severe
FXIII deficiency and history of intracranial hemorrhage aban-
doned to receive his prophylaxis. As FXIII acts in the final stage
of the coagulation cascade, such patients are not considered to
be in a general hypocoagulable state.8
In a published study on 12 autopsies, 4 deaths were
directly attributed to pulmonary embolism, and deep vein
thrombosis was observed in more than 50% of cases.9 Al-
though prolonged PT is a common finding in COVID-19, none
of four patients with available data in our study had pro-
longed PT times, which could be reflective of reduced
comparative disturbance of the coagulation system. While
concomitant activation of coagulation and fibrinolytic
















HB < 1% 50 M RT-PCR
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APTT: P
221 No







NA NA NA No






NA NA NA No
HA < 1% 47 M RT-PCR
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Asymptomatic Asymptomatic NA PT: N
APTT: P
125 No
HA > 30% 38 M RT-PCR Asymptomatic Asymptomatic NA NA NA No





FXIIID Severed 59 M CT scan Mild Cough NA NA NA No









N NA 315 No
Abbreviations: APTT, activated partial thromboplastin time; COVID-19, coronavirus disease 2019; CT, computed tomography; F, female; FXIIID, FXIII
deficiency; HA, hemophilia A; HB, hemophilia B; ICU, intensive care unit; M, male; N, normal; NA: Not available; P, prolonged; PT, prothrombin time;
RT-PCR, reverse transcriptase–polymerase chain reaction; VWD, von Willebrand disease.
aAll nonhospitalized patients considered mild, except asymptomatic ones.
bPatient was also affected by lymphoma.
cPatient had FVIII inhibitor.
dAbnormal clot solubility test.
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systems, and subsequent prolongation of PT, as well as
increased D-dimer and fibrin/fibrinogen degradation prod-
ucts, are common findings and risk factors presaging a poor
outcome in COVID-19,10 they were absent in this cohort
where tested, and we observed a more favorable outcome.
Moreover, thrombocytopenia, another common adverse fea-
ture of COVID-19,11 which can be attributed to concomitant
activation of the coagulation factors and fibrinolytic system,
was observed in only one of four patients. Viral associated
depletion of plateletsmay represent another characteristic of
patients with COVID-19, which can thus lead to potential
platelet consumption.12,13
It should be mentioned that one major limitation of our
study is the absence of all coagulation parameters in most
patients. Since being male is a risk factor for mortality, one
might expect that patientswith hemophiliawould potentially
be at a greater risk of more severe forms of COVID-19, but this
was not the experience in our cohort. Our findings thus
support our proposal that patients with CBDs, at least moder-
ately to severely affected individuals, are less susceptible to
hypercoagulability-related severe presentations in COVID-19,
for example, as reported following autopsy.9 Indeed, hyperco-
agulability may not be a big challenge for patients with
congenital hypocoagulability comparedwith the general pop-
ulation. There are some exceptions among patients with CBDs
who have a relatively higher tendency to thrombosis.14
Our findings are important in several aspects: a D-dimer
higher than 1 μg/mL, a clear adverse prognostic factor related
to a higher rate of morbidity and mortality,10 is less likely to
occur in patients with severe hypocoagulability states, partic-
ularly in severe FXIII deficiency.8 In addition, thrombocytope-
nia is shown to be accompanied by a higher rate of mortality
attributed inpart to intravascular coagulopathies and a state of
hyperfibrinolysis,which,again, is lessprobable inCBDstates. In
addition, thrombosis is considered one of the most common
causes of death in COVID-19. The rate of thrombosis is sub-
stantially lower in most patients with CBDs, with exception of
those with some conditions such as congenital fibrinogen
disorders and dysprothrombinemia.11 Therefore, this signifi-
cant adverse effect is less common in congenital hypocoagul-
ability states. It was suggested that instead of pulmonary
embolism, in situ pulmonary thrombosis can be considered
as one of the main causes of death in COVID-19.15 This
phenomenon could be attributed to direct virus invasion of
lung endothelial cells and local activation of hemostasis trig-
gered by the sustained underlying proinflammatory state. It is
postulated that subsequent release of a large amount of von
Willebrand factor swamps ADAMTS-13 (a disintegrin and
metalloproteinasewith a thrombospondin type 1motif, mem-
ber 13), resulting inplatelet aggregates and pulmonary throm-
bosis,15 a phenomenon that is less likely in some CBDs,
especially type 3 VWD and Bernard–Soulier’s syndrome, thus
making them less susceptible to any such related fatal event.16
In conclusion, it appears that a severe hypocoagulability
state may be protective against COVID-19 hypercoagul-
ability-related adverse effects, an important consideration
otherwisemaking anticoagulationmandatory for all patients
hospitalized with COVID-19. Some authors suggest mild
anticoagulant therapy, whereas others prefer more aggres-
sive therapeutic strategies.7 Nevertheless, although our data
are important, these observations are only confined to a
limited number of patients with CBDs; however, they war-
rant further, more extended studies, including our ongoing
study on a large number of patients with CBDs, which should
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